The clinical data: how much weight loss actually happens The table below summarizes weight-loss outcomes from the major Jardiance clinical trials
In June 2025 , WHO issued a safety alert regarding semaglutide medicines-Ozempic, Rybelsus, and Wegovy-linking their use to a very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION), potentially affecting up to 1 in 10,000 users
24 hours after taking certain diabetes medications (like insulin or sulfonylureas, if youre using them together with GLP-1s) Between meals, when blood sugar naturally dips During or after exercise, especially if you havent eaten enough beforehand After dose changes, as your body adapts to stronger appetite-suppressing effects During rapid weight loss or dietary changes, when your energy intake is lower than usual Whos at higher risk
PMC3521899
Regarding gastrointestinal tolerability, 83% of treated participants reported no or only mild key gastrointestinal adverse events